Bringing orphan drugs to the Japanese market

In recent years, Japan has seen considerable growth in research and development and approvals of drugs for the treatment of unmet medical needs and rare diseases.
The Japanese government has also established measures to promote research in these areas, and provides priority reviews and reduced filing fees for drugs that receive the orphan drug designation.
CMIC Group supports the efforts of overseas pharmaceutical companies, academia, and venture firms seeking to market orphan drugs.

Please select one of the following options.

Please select one of the following options.


Inquiries about our services

Click here if you are interested in outsourcing your operations to us.